This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.–Since its introduction by Sengstaken and Blakemore in 1950, esophageal balloon tamponade has been used throughout the world to control bleeding from esophageal varices. Abundant data indicate that balloon tamponade stops bleeding temporarily in 45% to 84% of patients. The disheartening feature of this form of treatment is that a majority of patients (80% in a two-year prospective study that we conducted) resume bleeding when the balloons are deflated. Moreover, in the experience of many workers, balloon tamponade is associated with an inordinate incidence of complications, including aspiration pneumonia, perforation of the esophagus, and asphyxia from slippage of the balloon up into the pharynx. Most important, a large amount of data have shown that balloon tamponade has failed to lower the mortality from bleeding varices in cirrhosis despite 24 years of wide-spread trial.
We have found that systemic intravenous injection of posterior pituitary extract (Pituitrin) (20 units
ORLOFF MJ. Whatever Became of the Esophageal Balloon Tube?-Reply. Arch Surg. 1974;109(3):458–459. doi:10.1001/archsurg.1974.01360030110034
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: